Join
Live feed
·
PRReleasevia Quantisnow
SAB Biotherapeutics Inc. logo

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

ByQuantisnow·Wall Street's wire, on your screen.
SABS· SAB Biotherapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SABS (SAB Biotherapeutics Inc.) and more on Quantisnow.